Home›Stock Screener›Bharat Immunologicals›Financial Statements

Bharat Immunologicals Complete Financial Statements

9 Years of Data
2023 - 2015

In FYNone, Bharat Immunologicals (BIBCL) reported revenue ₹9 Cr, net profit ₹-18 Cr and EPS ₹-4.20, with a net profit margin of -36.2% and ROE of -19.3%. Full financial statements from FY2015 to FY2023 (9 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Explore BIBCL value investing to estimate fundamental worth using multiple valuation models.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin -36.17% 2023 data
EBITDA Margin -34.04% 2023 data
Operating Margin -41.00% 2023 data
Return on Assets -9.14% 2023 data
Return on Equity -19.32% 2023 data

Balance Sheet Ratios

Current Ratio 5.50 2023 data
Equity Ratio 47.31% 2023 data
Asset Turnover 0.25 2023 data

BIBCL Revenue, Net Profit & EBITDA — Year-on-Year Growth

BIBCL YoY (March 2023 vs Period) — revenue -80.9%, net profit -5.9%, EBITDA -6.3%, expenses -60.3%. Review BIBCL price earnings ratio to evaluate earnings-based valuation against sector peers.

Revenue Growth
-80.9%
Year-over-Year
Net Profit Growth
-5.9%
Year-over-Year
EBITDA Growth
-6.3%
Year-over-Year
Expense Growth
-60.3%
Year-over-Year
Assets Growth
-12.7%
Year-over-Year
Equity Growth
-16.2%
Year-over-Year
Operating Cash Flow Growth
+126.2%
Year-over-Year
Financing Cash Flow Growth
-133.3%
Year-over-Year

BIBCL Income Statement — Revenue, EBITDA & Net Profit

Bharat Immunologicals revenue ₹9 Cr, EBITDA ₹-17 Cr, net profit ₹-18 Cr, EPS ₹-4.20 (None) — net profit margin -36.2%. For live price, earnings ratios and company overview, see Bharat Immunologicals stock price NSE.

Periods ₹ Crores
Particulars None March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016 March 2015
Revenue 9 47 80 87 68 88 36 125 129 147
Expenses 25 63 83 106 77 93 43 112 133 143
EBITDA -17 -16 -4 -19 -9 -5 -7 14 -4 4
Operating Profit Margin % -13.00% -41.00% -6.00% -24.00% -16.00% -11.00% -24.00% 10.00% -4.00% 2.00%
Depreciation 0 0 0 0 0 0 0 1 1 1
Interest 8 7 6 5 5 2 1 4 5 1
Profit Before Tax -25 -23 -10 -24 -14 -7 -8 9 -9 2
Tax 0 -6 -1 -6 -4 -2 -4 3 -3 1
Net Profit -18 -17 -9 -18 -10 -6 -4 7 -6 2
Earnings Per Share (₹) -4.20 -3.95 -2.03 1.10 -2.36 -1.34 -0.99 1.51 -1.44 0.36

BIBCL Balance Sheet — Assets, Liabilities & Shareholders' Equity

BIBCL total assets ₹186 Cr, total equity ₹88 Cr, total liabilities ₹ Cr (2023) — ROE -19.3%.

Years Annual Data ₹ Crores
Particulars 2023 2022 2021 2020 2019 2018 2017 2016 2015
ASSETS
Total Assets 186 213 104 127 125 53 59 68 80
Current Assets 33 65 34 93 99 38 47 60 74
Fixed Assets 115 116 4 5 5 5 5 6 6
Capital Work in Progress 0 0 32 0 0 0 0 0 0
Investments 0 0 0 0 0 0 0 0 0
Other Assets 70 97 68 122 120 48 53 63 74
LIABILITIES
Total Liabilities
Current Liabilities 6 6 6 6 6 3 3 3 4
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 88 105 34 21 31 38 42 35 41
Share Capital 43 43 43 43 43 43 43 43 43
Reserves & Surplus 45 62 -9 -23 -13 -6 -1 -8 -2

BIBCL Cash Flow Statement — Operating, Investing & Financing

Bharat Immunologicals operating cash flow ₹11 Cr, investing ₹1 Cr, financing ₹-15 Cr, net cash flow ₹-3 Cr (2023).

Periods ₹ Crores
Particulars March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016 March 2015
Operating Activities 11 -42 12 34 -32 3 -17 -9 8
Investing Activities 1 1 1 1 1 -1 1 1 0
Financing Activities -15 45 -12 -34 31 -1 -3 -2 -1
Net Cash Flow -3 3 0 1 -1 1 -20 -10 7